Holen Sie sich die Stockscreener-App
8.94
5.55%
0.47
Handel nachbörslich:
9.03
0.09
+1.01%
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - BioSpace
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Personalis NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - Moomoo
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Medicare Expands Coverage for Personalis NeXT Personal Test - TipRanks
US agency broadens coverage of Personalis breast cancer test - MSN
Expanded Medicare covers Personalis (NASDAQ: PSNL) NeXT Personal cancer test - Stock Titan
Personalis gains expanded Medicare coverage for breast cancer test By Investing.com - Investing.com Nigeria
US Agency Broadens Coverage Of Personalis Breast Cancer Test - Benzinga
Personalis Shares Rise After NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid - marketscreener.com
Personalis (PSNL) Shares Climb on Expanded Medicare Coverage for NeXT Personal Test - GuruFocus
Personalis (PSNL) Expands Medicare Coverage for NeXT Personal Te - GuruFocus
Personalis gets expanded Medicare coverage for NeXT Personal - Seeking Alpha
Personalis secures fourth Medicare coverage decision for Next Personal, expanding breast cancer coverage to pre-surgical treatment monitoring - marketscreener.com
Personalis gains expanded Medicare coverage for breast cancer test - Investing.com
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
PSNL Stock Price, Quote & Chart | PERSONALIS INC (NASDAQ:PSNL) - ChartMill
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Personalis Secure Medicare Coverage For NeXT Personal MRD Test In Immunotherapy Monitoring; Stock Up - RTTNews
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis gains expanded Medicare coverage for cancer test - Investing.com UK
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com South Africa
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
1.19%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):